(AGENPARL) - Roma, 7 Gennaio 2025 - (AGENPARL) – mar 07 gennaio 2025 Lund, Sweden, 7 January 2025. Hansa Biopharma AB, “Hansa” or the “Company”
(Nasdaq Stockholm: HNSA), today announced that management will attend the 43[rd]
Annual J.P. Morgan Healthcare Conference. If you are interested in a meeting,
The Company has achieved several key milestones in the last 12-months across its
three key therapeutic areas: Autoimmune, Gene Therapy and Transplantation.
In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase
2 trial in Guillain Barre Syndrome (GBS) and indirect treatment comparison to
the International Guillain-Barré Syndrome Outcome Study (IGOS) demonstrating the
potential of imlifidase, the Company’s first-generation IgG cleaving molecule,
to address a significant unmet need in GBS. Additionally, the GOOD-IDES-02
(Phase 3 trial in anti-GBM) completed enrolment and positive results from the
NICE-01 Phase 1 trial and additional 12-month analysis for HNSA-5487, the
Company’s second-generation IgG cleaving molecule, demonstrated rapid and robust
IgG reduction and redosing potential.
In Gene Therapy, the Company initiated two trials with gene therapy partners:
SRP-9001-104 Phase 1b trial in Duchenne Muscular Dystrophy (DMD) with Sarepta
Therapeutics, Inc. (Nasdaq: SRPT) and GNT-018-IDES Phase 2 trial in Crigler
-Najjar Syndrome with Genethon. In both trials, imlifidase is being evaluated as
a pre-treatment to gene therapy in patients with anti-AAV antibodies.
In Transplantation, randomization of the ConfIdeS (pivotal US Phase 3 trial in
kidney transplantation) trial was completed. The Company had four consecutive
quarters of strong IDEFIRIX (imlifidase) sales across Europe with Q3 2024 being
the highest ever quarterly IDEFIRIX sales performance (69.5 MSEK/$6.4M),
underscoring the important role that IDEFIRIX can play in desensitization in
kidney transplantation.
In 2025, the Company has several key milestones:
· Data read out of the pivotal US Phase 3 ConfIdeS trial for imlifidase and
submission of a Biologics License Application (BLA) to the US Food and Drug
Administration (FDA) in 2H 2025
· Data read out of Sarepta Therapeutics’ Phase 1b trial SRP-9001-104 in DMD
(2H 2025)
· Data read out of the GOOD-IDES-02 Phase 3 trial in anti-GBM
· HNSA-5487 development pathway alignment with regulatory agencies in neuro
-autoimmune diseases (1H 2025) with an initial focus in myasthenia gravis (MG)
Hansa is developing novel immunomodulating biologic therapies based on its
proprietary, first in class IgG cleaving platform and is focused on IgG-driven
immune mediated diseases. The Company has two IgG cleaving compounds including
imlifidase, a first generation, first in class, single dose therapy with proven
efficacy and safety and HNSA-5487, a second-generation IgG cleaving molecule
with redosing potential. Imlifidase is conditionally approved in the EU for
desensitization in kidney transplantation, with late-stage trials in autoimmune
diseases where IgG is a driver of disease, and as a pre-treatment to gene
therapy in patients with anti-AAV antibodies.
— ENDS —
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
Stephanie Kenney, VP Global Corporate Affairs
Notes to editors
About Imlifidase
Imlifidase is a unique antibody-cleaving enzyme originating from Streptococcus
pyogenes that specifically targets IgG and inhibits IgG-mediated immune
response.[1] It has a rapid onset of action, cleaving IgG-antibodies and
inhibiting their activity within hours after administration. Imlifidase is
conditionally approved in Europe and is marketed under the trade name
IDEFIRIX[®] for the desensitization treatment of highly sensitized adult kidney
transplant patients with a positive crossmatch against an available deceased
donor.[1] Full product information can be accessed via the initial Summary of
Product
Characteristics found here (https://www.ema.europa.eu/en/documents/product
-information/idefirix-epar-product-information_en.pdf).
About HNSA-5487
HNSA-5487 is Hansa Biopharma’s second-generation IgG-cleaving enzyme with the
potential to prolong the IgG-low window and redosing potential. In the NICE-01
Phase 1b trial, HNSA-5487 demonstrated rapid and highly robust reduction of IgG
levels by more than 95 percent within a few hours post treatment. In a 12-month
follow up analysis IgG levels returned to normal range six months after initial
dosing. This confirms that HNSA-5487 mirrors the extremely high efficacy of
imlifidase, the Company’s first-generation IgG-cleaving enzyme, in reducing
total IgG levels. No serious adverse events were observed and as previously
communicated HNSA-5487 is safe and well tolerated.
About Hansa and Kidney Transplantation
Kidney disease can progress to kidney failure or End-Stage Renal Disease (ESRD),
identified when a patient’s kidney function is less than 15%.[2] ESRD poses a
significant health burden, affecting nearly 2.5 million patients worldwide.[2] A
kidney transplant is the treatment of choice for suitable patients with ESRD
because it offers improved survival and quality of life benefits, and is cost
savings compared to long-term dialysis. There are approximately 170,000 kidney
patients in the U.S. and Europe waiting for a new kidney.[3]
Highly sensitized kidney transplant patients have pre-formed antibodies called
donor specific antibodies (DSAs) with a broad reactivity against human leukocyte
antigens (HLAs), which can cause tissue damage and potentially transplant
rejection.[4] The presence of DSAs means that highly sensitized patients tend to
have limited or no access to transplant, as finding a compatible donor organ can
be particularly challenging.[5,6] The complexity of their immunological profile
means that highly sensitized patients spend longer time than average on
transplant waiting lists, with evidence showing that this longer time waiting
for a suitable donor relates to an increased mortality risk.[7,8] Across the
U.S. and Europe, highly sensitized patients comprise around 10-15% of the total
of patients on transplant waiting lists.[9,10]
Imlifidase is a promising new strategy for desensitization of transplant
patients with donor-specific anti-HLA (Human Leukocyte Antigens) antibodies
(DSAs).[11] Highly sensitized patients have high levels of these preformed
antibodies that can bind to the donor organ and damage the transplant.[4] Once
they are inactivated with imlifidase, there is a window of opportunity for the
transplant to take place. By the time the body starts to synthesize new IgG, the
patient will be receiving post-transplant immunosuppressive therapy to reduce
the risk of organ rejection.
The efficacy and safety of imlifidase as a pre-transplant treatment to reduce
donor-specific IgG was studied in four Phase 2 open-label, single-arm, six-month
clinical trials.[10-13] Hansa is collecting further clinical evidence and will
submit additional efficacy and safety data based on one observational follow-up
study and one post authorization efficacy study (PAES).
About Hansa and Autoimmune Diseases
Autoimmune diseases form a group of serious diseases caused by the immune system
attacking the body. In many autoimmune diseases the immune system mistakenly
recognizes the body’s own proteins, as foreign and mounts an immune response,
creating antibodies to attack the body’s own cells and tissues.[14-16]
Pathogenic IgG can contribute to a broad spectrum of autoimmune diseases.
Hansa Biopharma is exploring how imlifidase and HNSA-5487 may be able to prevent
or slow the progression of these diseases and their debilitating, life
-threatening symptoms. Imlifidase is currently being studied in the following
autoimmune diseases: anti-glomerular basement membrane (anti-GBM) disease and
Guillain-Barré Syndrome (GBS). HNSA-5487 is moving quickly into the clinical
phase focusing on patients with myasthenia gravis (MG) and potentially other
neuro-autoimmune diseases.
About Hansa and Gene Therapy
Imlifidase is currently being evaluated as a pre-treatment to gene therapy in
areas of high unmet need. Many gene therapies are based on the use of Adeno
Associated Viruses (AAV) vectors.[17-19] In some patients the immune system
carries antibodies that counteract the gene therapy treatment preventing its
success.[18-24] Pre-treatment with imlifidase prior to AAV-based gene therapy
treatment has the potential to inactivate antibodies and thereby enable gene
therapy in patients with pre-existing antibodies to AAV-based gene
therapies.[23] It is estimated that anti-AAV antibodies on average prevent 1 in
3 people from benefiting from gene therapy treatments.[18-21]
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a
mission to develop and commercialize innovative, lifesaving and life-altering
treatments for patients with rare immunological conditions. The Company has a
rich and expanding research and development program based on its proprietary IgG
-cleaving enzyme technology platform, to address serious unmet medical needs in
autoimmune diseases, gene therapy and transplantation. The Company’s portfolio
includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving
enzyme therapy, which has been shown to enable kidney transplantation in highly
sensitized patients and HNSA-5487, a second-generation IgG cleaving molecule
with redosing potential. Hansa Biopharma is based in Lund, Sweden, and has
operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm
under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on
LinkedIn (https://www.linkedin.com/company/hansa-medical-ab/).
©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and
IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All
rights reserved.
References
1. European Medicines Agency. Idefirix[®] summary of product characteristics.
Available at: https://www.ema.europa.eu/en/documents/product
-information/idefirix-epar-product-information_en.pdf.
2. NIH (2018). What is kidney failure? Available at:
https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/what
-is-kidney-failure.
3. Newsletter Transplant 2022. International figures on donation and
transplantation. Available at: Newsletter Transplant – latest edition I Freepub
(edgm.eu) Accessed: May 2024.
4. Eurostam Report (A Europe-wide strategy to enhance transplantation of highly
sensitized patients on the basis of acceptable HLA mismatches.) Available
at https://cordis.europa.eu/project/id/305385/reporting.
5. Redfield RR, et al. The mode of sensitization and its influence on allograft
outcomes in highly sensitized kidney transplant recipients. Nephrol Dial
Transplant. 2016 Oct;31(10):1746-53. doi: 10.1093/ndt/gfw099.
6. Lonze BE, et al. IdeS (Imlifidase): A Novel Agent That Cleaves Human IgG and
Permits Successful Kidney Transplantation Across High-strength Donor-specific
Antibody. Ann Surg. 2018 Sep;268(3):488-496. doi: 10.1097/
7. Alelign T, Ahmed MM, Bobosha K, Tadesse Y, Howe R, Petros B. Kidney
Transplantation: The Challenge of Human Leukocyte Antigen and Its Therapeutic
8. Heidt S, et al. Highly Sensitized Patients are Well Serves by Recieving a
Compatible Organ Offer Based on Acceptable Mismatches. Front Immunol.
9. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry
of Transplant Recipients (SRTR). OPTN/SRTR 2022 Annual Data Report. U.S.
Department of Health and Human Services, Health Resources and Services
Administration; 2024. Accessed [June 2024].
10. Jordan SC, et al. Imlifidase Desensitization in Crossmatch-positive, Highly
Sensitized Kidney Transplant Recipients: Results of an International Phase 2
Trial (Highdes). Transplantation. 2021 Aug 1;105(8):1808-1817. doi:
11. Jordan SC, et al. IgG Endopeptidase in Highly Sensitized Patients Undergoing
Transplantation. N Engl J Med 2017;377:442-453. DOI: 10.1056/NEJMoa16125
12. Winstedt L, et al. Complete Removal of Extracellular IgG Antibodies in a
Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS–A Novel
13. Lorant T, et al. Safety, immunogenicity, pharmacokinetics, and efficacy of
degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney
disease patients. Am J Transplant. 2018 Nov;18(11):2752-2762. doi:
10.1111/ajt.14733.
14. Angum F, et al. The Prevalence of Autoimmune Disorders in Women: A Narrative
Review. Cureus. 2020 May. 12(5):e8094. doi: 10.7759/cureus.8094.
15. Wang L, et al. Human autoimmune diseases: a comprehensive update. J Intern
Med. 2015 Oct;278(4):369-95. doi: 10.1111/joim.12395.
16. Ma H, Murphy C, Loscher CE and O’Kennedy R (2022) Autoantibodies – enemies,
and/or potential allies? Front. Immunol. 13:953726. doi:
10.3389/fimmu.2022.953726
17. Lundstrom K. Viral Vectors in Gene Therapy: Where Do We Stand in 2023?
18. Boutin S, et al. Prevalence of serum IgG and neutralizing factors against
adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy
population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010
19. Calcedo R, Wilson JM. Humoral Immune Response to AAV. Front Immunol. 2013
20. Veron P, Leborgne C, Monteilhet V, Boutin S, Martin S, Moullier P, Masurier
C. Humoral and cellular capsid-specific immune responses to adeno-associated
virus type 1 in randomized healthy donors. J Immunol. 2012 Jun 15;188(12):6418
21. Kruzik A, et al. Prevalence of Anti-Adeno-Associated Virus Immune Responses
in International Cohorts of Healthy Donors. Mol Ther Methods Clin Dev. 2019 Jun
22. Falese L, et al. Strategy to detect pre-existing immunity to AAV gene
therapy. Gene Ther. 2017 Dec;24(12):768-778. doi: 10.1038/gt.2017.95. Epub 2017
23. Leborgne C, et al. IgG-cleaving endopeptidase enables in vivo gene therapy
in the presence of anti-AAV neutralizing antibodies. Nat Med. 2020
Jul;26(7):1096-1101. doi: 10.1038/s41591-020-0911-7. Epub 2020 Jun 1. PMID:
24. Au H.K, et al. (2022) Gene Therapy Advances: A Meta-Analysis of AAV Usage in
Clinical Settings. Front. Med. 8:809118. doi: 10.3389/fmed.2021.809118
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/nky642kFX69xWT8XGE88bQVjDj9LDsTw5WYmUgb5JC2pWL5yf1gYCrqvZhcymncHMdq31sHo5kf1tyoYkez2dRKQcHVw8oXV6F6wdWYDMp647.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/nky642kFX69xWT8XGE88bQVjDj9LDsTw5WYmUgb5JC2pWL5yf1gYCrqvZhcymncHMdq31sHo5kf1tyoYkez2dRKQcHVw8oXV6F6wdWYDMp647.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
Report this content
Trending
- Rauti: Manzi (Pd), Giuli chiarisca il patrocinio del Ministero alla mostra alla Camera, chi al MiC ha esaminato materiali?
- Doppio Diploma Italia-USA: come ottenere la maturità americana studiando online in Italia
- Comunicato Stampa 2031/2026 Tavolo Pastificio Rigo di Pieve del Grappa (TREVISO). Bitonci, “Essenziale tutelare continuità industriale e lavoro. Pessima la scelta del gruppo Clemens Products che esclude anche la cessione dello stabilimento ai lavoratori
- Casa, Mazzetti (FI): “Basta vessare i cittadini per difformità minori. Serve una regolarizzazione semplice, veloce e giusta per rispondere alle esigenze della popolazione”
- Manovra: Fossi (Pd), 60 milioni per tutelare e valorizzare la Via Francigena
- RAI, PELUFFO (PD): PIANO IMMOBILIARE AL CAPOLINEA? I VERTICI FACCIANO CHIAREZZA
- SCUOLA, SPERANZON (FDI): ASSESSORE PD INCITA ALLE OCCUPAZIONI, GRAVISSIMO
- Sicurezza, Ciani: governo spieghi posizione su ronde social a Roma
- Camera dei deputati: Coperture Centemero
- Armi nucleari in Europa, Mosca avverte Lituania e Polonia: possibili contromisure se cambiano le restrizioni